# Virios Therapeutics (VIRI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VIRI
## Company Profile
- Ticker: VIRI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Infectious Disease
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
### Non-Opioid Pain Company
Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy.
### Halneuron
Halneuron is an investigational non-opioid analgesic being evaluated for chemotherapy-induced neuropathic pain. The program is designed to provide durable pain reduction without the risks associated with chronic opioid treatment.
### Long-Term Extension
A Phase 2b extension study evaluates pain reduction over three months of Halneuron treatment after completion of the core four-week study.
### SP16
SP16 is an FDA-cleared investigational program for chemotherapy-induced pain and peripheral neuropathy being advanced through an NCI-funded academic study.
## Why The Stock Is Moving

Current closing-price context is not available for VIRI.

## Future Catalysts

- Topline results from the Phase 2b Halneuron study in chemotherapy-induced neuropathic pain in fall 2026.
- Initiation of the NCI-funded SP16 study in chemotherapy-induced pain and peripheral neuropathy in the second half of 2026.

## Recent News
- 2026-08-17 12:30 EST — [Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026](https://biopharmsignal.com/news/VIRI/dogwood-to-host-virtual-kol-event-to-discuss-halneuron-for-the-treatment-of-chem-91a0089d) — Source: Virios Therapeutics
- 2026-08-13 12:30 EST — [Dogwood Therapeutics Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-second-quarter-2026-financial-results-d09fce06) — Source: Virios Therapeutics
- 2026-07-20 12:30 EST — [Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026](https://biopharmsignal.com/news/VIRI/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-chemotherapy-in-dd9f404d) — Source: Virios Therapeutics
- 2026-06-30 12:45 EST — [Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-appoints-iain-dukes-venture-partner-at-orbimed-as-chair-of--8101d663) — Source: Virios Therapeutics
- 2026-05-18 12:45 EST — [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-commencement-of-halneuronr-chemotherapy-induced-neuropathic-pain-phase-2b-long-term-extension-study) — Source: Virios Therapeutics